New data published by the Center for Public Health Law Research (CPHLR) at Temple University Beasley School of Law offer an in-depth look at prior authorization policies that apply to children younger than 18 in Medicaid managed care plans. The data capture details of Medicaid managed care policies for the 50 U.S. states and the District of Columbia, describing policies governing access to ADHD medications as of Oct. 1, 2025, including prior authorization and age requirements and prerequisites for nonmedication alternatives.
❓ Unknown
Analysis of ADHD Medication Access Policies in U.S. Medicaid Managed Care Plans
5d ago
September 11, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
The Center for Public Health Law Research at Temple University has released new data on prior authorization policies for ADHD medications in Medicaid managed care plans affecting children under 18. This study encompasses all 50 U.S. states and the District of Columbia, detailing access policies as of October 1, 2025. While the article focuses on U.S. healthcare, it highlights broader issues of healthcare access that could resonate in Iran's own healthcare discussions.
🔍 Quick Context Guide
💡 Bottom Line:
Understanding U.S. Medicaid policies on ADHD medications can provide insights for Iran's healthcare discussions.
👥 Key Players
Center for Public Health Law Research (CPHLR)
MENTIONED
Research organization
"They provide data and analysis on public health policies that can influence healthcare discussions globally, including in Iran."
Medicaid
MENTIONED
U.S. government health insurance program
"Medicaid policies can serve as a model or cautionary tale for healthcare systems in other countries, including Iran."
📰 What Happened
New data from CPHLR reveals the prior authorization policies for ADHD medications in Medicaid managed care plans for children under 18 across the U.S. This data highlights the complexities of accessing necessary medications.
- The study covers all 50 U.S. states and the District of Columbia.
- It focuses on policies as of October 1, 2025, detailing access requirements for ADHD medications.
💡 Why It Matters
🇮🇷 For Iran: The findings may prompt Iranian policymakers to examine their own healthcare access issues, particularly for mental health medications.
🌍 Regional: Access to medications is a critical issue in many Middle Eastern countries, and this study could influence regional healthcare policies.
🌐 International: The U.S. approach to medication access can inform international debates on healthcare equity and access.
📚 Background
ADHD is a common mental health condition affecting children, and access to effective medications is crucial for treatment. Medicaid's policies reflect broader healthcare access issues.
Mental health policy
Healthcare access and equity
📡 Source:
NEUTRAL
📊 Confidence:
70%
The CPHLR is a research organization that aims to provide objective data and analysis.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
26 min ago •
Brazilian Sedge Reproduces Sexually Without Genetic Reshuffling, Producing Clonal Offspring
26 min ago •
H5N1 Bird Flu Claims Life of Australian Sea Lion, Raises Concerns for Marine Wildlife
35 min ago •
Palestinians Rely on Local Radio for Updates Amid Israeli Attacks
36 min ago •
Scientists Successfully Transport Antiprotons by Road for the First Time
36 min ago •